The strategic objective of WP2 is to co-ordinate all regulatory
information relating to the project in preparation for carrying out
all clinical trials and submission of the Paediatric Use Medicines
WP2 is led by Diurnal Limited. The development of the Paediatric
Investigation Plan (PIP) and PUMA in relation to the work being
undertaken by the TAIN project will be controlled and coordinated
by activities from WP2.
TAIN is funded by European Commission FP7 Programme HEALTH